



Financial Tear Sheet

Primary IR Contact

Steve Deitsch
 BioScrip, Inc.
 Phone: (720) 697-5150
 E-mail: stephen.deitsch@bioscrip.com

Corporate Profile

BioScrip, Inc. is a leading national provider of infusion and home care management solutions. BioScrip partners with physicians, hospital systems, skilled nursing facilities, healthcare payors, and pharmaceutical manufacturers to provide patients access to post-acute care services. BioScrip operates with a commitment to bring customer-focused pharmacy and related healthcare infusion therapy services into the home or alternate-site setting. By collaborating with the full spectrum of healthcare professionals and the patient, BioScrip provides cost-effective care that is driven by clinical excellence, customer service, and values that promote positive outcomes and an enhanced quality of life for those it serves. BioScrip provides its infusion and home care services from over 70 locations across 28 states.

BioScrip also offers complete Pharmacy Benefit Management programs that include customized benefit plan design, pharmacy network management and sophisticated reporting capabilities that deliver improved clinical and economic outcomes.

Stock Performance

BIOS (Common Stock)	
Exchange	NASDAQ (US Dollar)
Price	\$2.68
Change (%)	▲ 0.06 (2.29%)
Volume	1,546,676
52 Week Low	\$0.98
Market Cap	\$324,233,215
Rolling EPS	-0.50
PE Ratio	0
Shares Outstanding	120,982,543



Data as of 06/23/17 4:00 p.m. ET

Recent Headlines


- 05/30/17 - 8:00 a.m.
[BioScrip Provides Update on UnitedHealthcare Contract](#)
- 05/24/17 - 8:01 a.m.
[BioScrip to Present at the Jefferies 2017 Global Healthcare Conference](#)
- 05/04/17 - 8:01 a.m.
[BioScrip Reports First Quarter 2017 Financial Results](#)

Events

There are currently no events scheduled.

Analyst Estimates / Ratings

Mean Recommendation: 1.7



EPS Trend		Current	30 Days Ago	90 Days Ago
QTR	Jun 17	-0.13	-0.13	-0.10
QTR	Sep 17	-0.07	-0.08	-0.06
QTR	Dec 17	-0.03	-0.04	-0.02
QTR	Mar 18	-0.11	-0.11	-0.11
FY	Dec 17	-0.43	-0.42	-0.30
FY	Dec 18	-0.26	-0.26	-0.13

SEC Filings

Filing Date	Form
06/07/17	SC 13G

Corporate Governance

Dan Greenleaf President & Chief Executive Officer

05/04/17	4	Steve Deitsch	Senior Vice President Chief Financial Officer & Treasurer
05/04/17	4	David Evans	Senior Vice President Chief Operating Officer including Clinical Services
05/04/17	4	Kathryn Stalmack	Senior Vice President General Counsel
		Alex Schott	Senior Vice President Strategic Operations
		Jody Kepler	Senior Vice President Chief Compliance Officer
		Taylor Erickson	Senior Vice President Chief Information Officer
		Bet Rosa	Senior Vice President of Human Resources
		Bob Roose	Senior Vice President Chief Procurement Officer
		Britt Jeffcoat	Vice President Controller & Chief Accounting Officer
		Kelly Aldridge	Vice President Sales & Marketing

Ownership Summary

Shareholders				
	Holders	Value (\$MM)	% O/S	Shares
Institution	149	202.45	95.1	115,084,779
Mutual Fund	157	55.13	28.5	34,481,118
Insider *	8	1.06	0.5	656,775

*Insider values reflect direct beneficial ownership.

Top Holders				
	Shares Held	% O/S	Share Change	Filing Date
Gabelli Funds, LLC	13,304,002	11.0	-2,862,450	03/31/17
Gilder Gagnon Howe & Co. LLC	13,171,469	10.9	8,805,743	05/31/17
Venor Capital Management LP	12,005,453	9.9	12,005,453	03/31/17
Camber Capital Management LLC	10,180,000	8.4	0	03/31/17
Coliseum Capital Management, L.L.C.	5,622,410	4.7	0	03/31/17
Ardsley Partners	5,280,000	4.4	-1,070,000	03/31/17
BlackRock Institutional Trust Company, N.A.	5,172,906	4.3	-6,027	03/31/17
Diamond Hill Capital Management Inc.	5,151,236	4.3	-154,164	03/31/17
Fidelity Institutional Asset Management	4,803,000	4.0	1,273,205	03/31/17
The Vanguard Group, Inc.	4,348,049	3.6	-27,998	03/31/17

Data provided by Nasdaq. Minimum 15 minutes delayed.
Minimum 20 minutes delayed